Haemonetics (HAE) Stock
Global blood management systems and software provider. Here's the price, business snapshot, and what's worth knowing about Haemonetics in September 2026.
Haemonetics Corporation (HAE) supplies blood- and plasma-management systems, disposables and software to hospitals, blood centres and plasma collectors worldwide. Investors should know the business mixes recurring revenue from consumables with equipment sales and service contracts, which can provide revenue visibility but is sensitive to procedure volumes and reimbursement. The company competes on product innovation, supply reliability and regulatory compliance; acquisitions and new product roll-outs can support growth but also carry execution risk. Key risks include regulatory change, reimbursement pressure, cyclic healthcare spending and competition from larger medical-device companies. With a market capitalisation around $2.47bn, HAE can appeal to those seeking exposure to specialised medical devices, though it may be more volatile than large-cap healthcare names. This is general educational information, not personal advice — values can rise and fall and returns are not guaranteed. Consult your financial adviser to assess whether this stock fits your objectives and risk tolerance.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Haemonetics stock with a target price of $111, indicating potential growth.
Financial Health
Haemonetics is performing well with strong revenue, cash flow, and profit margins.
Dividend
Haemonetics Corp does not currently pay a dividend, which is common for companies reinvesting profits for growth. If you invested $1000, you would receive $0 a year in dividends.
Why You’ll Want to Watch This Stock
Recurring Revenue Mix
Consumables and service contracts provide steady revenue streams, offering predictability, though performance can vary with procedure volumes and reimbursement.
Product Innovation Focus
New devices and software can drive market share and margins, but R&D, regulatory approval and execution risk can affect outcomes.
Global Market Exposure
A presence across hospitals and blood centres gives geographic diversification, yet differing regulations and healthcare budgets can create varied performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
